LLY · Full Picture

ELI LILLY & Co — the full picture

Earnings window · 2026-08-05 to 2026-11-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Guidance and Outlook · Guidance & outlookPriority 94
    +20.4% revenue; 3 sources (news, press_release, sec_filing); 6 forward row(s); quote_verified
    Lilly raised 2026 full-year revenue guidance from $85–$87 billion to $91–$92 billion.
  2. Revenue Performance and Mix · Revenue growth & mixPriority 93
    -4.1% revenue; 4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); structured_verified
    Eli Lilly reported Q2 revenue growth of 47.70% to USD 22.97 billion, driven by sales of Mounjaro and Zepbound.
  3. Manufacturing Capacity · Supply chain & operationsPriority 87
    +9.2% assets; 4 sources (news, press_release, sec_filing, transcript); 6 forward row(s); quote_verified
    Eli Lilly broke ground on a new $6.5 billion manufacturing facility in Houston aimed at expanding GLP-1 capacity.
  4. Market Demand - Anti-Obesity · Demand, orders & backlogPriority 85
    +120.6% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); quote_verified
    Company stock exceeded $1,000 per share and the company became the first pharma to surpass a $1 trillion market cap following obesity drug success, with shares having surged over 285% since 2022.
  5. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 82
    -1.8% cash; 4 sources (news, press_release, sec_filing, transcript); 4 forward row(s); structured_verified
    In Q2 2026, the company recognized acquired IPR&D charges of $2,776 million compared with $154 million in Q2 2025.
  6. Acquired IPR&D Charges · M&A and divestituresPriority 80
    -15.4% operating_income (realized); 3 sources (press_release, sec_filing, transcript); quote_verified
    Lilly recognized Q3 2026 acquired IPR&D charges of $4.2 billion, compared with $656 million in Q3 2025; the 2026 charges primarily related to the AtaiBeckley and Curevo acquisitions.
  7. 2026 Financial Guidance Update · Guidance & outlookPriority 78
    +9.2% revenue; 2 sources (news, transcript); 3 forward row(s); quote_verified
    Slide 14 guidance update: Lilly increased the low end of its 2026 revenue range by $3 billion and the high end by $2 billion; now expects full-year revenue between $85 billion and $87 billion.
  8. Product Revenue - Mounjaro and Zepbound · UnclassifiedPriority 76
    +92.3% revenue (realized); 3 sources (news, press_release, transcript); quote_verified
    Lilly's Q3 2026 Mounjaro worldwide revenue increased 65% to $10.7 billion; U.S. revenue was $5.0 billion, up 41%, and revenue outside the U.S. increased 93% to $5.7 billion.
  9. Capital Expenditure Program · Capital expenditurePriority 72
    -7.8% cash; 2 sources (news, transcript); 6 forward row(s); quote_verified
    Lilly broke ground on a $5 billion manufacturing facility in Richmond, Virginia.
  10. Outstanding Indebtedness · Debt, leverage & refinancingPriority 69
    -15.1% liability (realized); structured_verified
    In May 2026, the Company issued long-term debt totaling $9.0 billion and used net cash proceeds for general corporate purposes including repayment of outstanding commercial paper and funding portion of upfront cash consideration for acquisitions of Centessa and Kelonia.
  11. Revenue Concentration Risk · Customers & concentrationPriority 66
    +2.9% revenue; 2 sources (news, sec_filing); 2 forward row(s); quote_verified
    The current consensus estimate forecasts Eli Lilly's revenue for the upcoming quarter to be $22.11 billion, indicating a 25.59% growth compared to the corresponding quarter of the prior year.
  12. Operating Expense Trends · Operating expenses (SG&A)Priority 65
    -5.0% operating_income (realized); 3 sources (press_release, sec_filing, transcript); quote_verified
    Q3 2026 research and development expenses increased 23% to $4.2 billion, or 17% of revenue, driven by investments in Lilly's early- and late-stage portfolio.

Threads by pillar

Revenue & Demand Priority 98 · 12 threads

Costs & Margins Priority 94 · 7 threads

Capital & Balance Sheet Priority 90 · 7 threads

Strategy & Portfolio Priority 92 · 12 threads

Legal, Regulatory & Policy Priority 74 · 10 threads

Guidance & Outlook Priority 95 · 2 threads

Macro & Market Conditions Priority 64 · 3 threads

Management & Governance Priority 31 · 1 thread

Shareholders & Street Priority 10 · 1 thread

Unclassified Priority 91 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
revenue+28.1%+37.0%+392.0%
assets+16.9%+16.9%+11.5%
cash-16.1%+16.1%-11.7%
margin+3.8%+3.8%+2.8%
liability-3.0%+3.0%-19.8%
operating_income-0.4%+0.4%-35.6%
net_income——+7.3%